Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Shanxi University of Chinese Medicine, Jinzhong, 030619, Shanxi, China.
Stem Cell Res Ther. 2021 Nov 9;12(1):567. doi: 10.1186/s13287-021-02635-9.
Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from mesoderm during early development that are characterized by high self-renewal ability and multidirectional differentiation potential. These cells are present various tissues in the human body and can be cultured in vitro. Under specific conditions, MSCs can differentiate into osteoblasts, neuron-like cells, adipocytes and muscle cells and so on, therefore, have a great application value in cell replacement therapy and tissue repair. In recent years, the application of MSCs in rheumatic diseases has received increasing attention. On the one hand, MSCs have the ability to differentiate into bone and cartilage cells; on the other hand, these stem cells are also involved in immune regulation, resulting in the alleviation of inflammation and anti-fibrotic properties and the promotion of vascular repair, thus bringing new hope for the treatment of rheumatic diseases. This article reviews the clinical progress in MSC application for the treatment of rheumatic diseases.
间充质干细胞（MSCs）是来源于早期发育中中胚层的多能干细胞，其特征在于高自我更新能力和多向分化潜能。这些细胞存在于人体的各种组织中，并可在体外培养。在特定条件下，MSCs 可以分化为成骨细胞、神经元样细胞、脂肪细胞和肌肉细胞等，因此在细胞替代治疗和组织修复方面具有巨大的应用价值。近年来，MSCs 在风湿性疾病中的应用受到了越来越多的关注。一方面，MSCs 具有分化为骨和软骨细胞的能力；另一方面，这些干细胞还参与免疫调节，从而减轻炎症和抗纤维化特性并促进血管修复，为风湿性疾病的治疗带来了新的希望。本文综述了 MSCs 在治疗风湿性疾病中的临床应用进展。
